Résumé
A 16-yr-old girl received liver transplantation for fulminant hepatitis. Aplastic anemia developed, and she received hematopoietic stem cell transplantation (HSCT). Eleven months after liver transplantation, abdominal lymph node enlargement and colon ulcers were observed, and colon biopsy showed posttransplant lymphoproliferative disorder (PTLD). Immunosuppression reduction was attempted, but it produced no therapeutic effect. Fourteen months after liver transplantation, she received a second HSCT due to engraftment failure, and PTLD resolved completely. The second HSCT can serve as cellular therapy for PTLD.
Sujets)
Adolescent , Femelle , Humains , Transplantation de cellules souches hématopoïétiques/méthodes , Transplantation hépatique/effets indésirables , Syndromes lymphoprolifératifs/étiologie , Résultat thérapeutiqueRésumé
Sunitinib is an oral tyrosine kinase inhibitor with anti-angiogenic activity that is used for the treatment of advanced renal cell carcinoma and advanced gastrointestinal stromal tumors after failure on imatinib. The most common adverse effects of sunitinib are fatigue, diarrhea, nausea, stomatitis, hypertension, hand-foot syndrome, and cytopenia. Sunitinib was recently reported to be associatedwith reversible posterior leukoencephalopathy syndrome (RPLS). Here, we report the case of a 76-year-old woman with sunitinib- induced RPLS that developed after rifampin discontinuation.
Sujets)
Sujet âgé , Femelle , Humains , Benzamides , Néphrocarcinome , Diarrhée , Fatigue , Tumeurs stromales gastro-intestinales , Syndrome mains-pieds , Hypertension artérielle , Indoles , Nausée , Pipérazines , Leucoencéphalopathie postérieure , Protein-tyrosine kinases , Pyrimidines , Pyrroles , Rifampicine , Stomatite , Mésilate d'imatinibRésumé
Sunitinib is an oral tyrosine kinase inhibitor with anti-angiogenic activity that is used for the treatment of advanced renal cell carcinoma and advanced gastrointestinal stromal tumors after failure on imatinib. The most common adverse effects of sunitinib are fatigue, diarrhea, nausea, stomatitis, hypertension, hand-foot syndrome, and cytopenia. Sunitinib was recently reported to be associatedwith reversible posterior leukoencephalopathy syndrome (RPLS). Here, we report the case of a 76-year-old woman with sunitinib- induced RPLS that developed after rifampin discontinuation.
Sujets)
Sujet âgé , Femelle , Humains , Benzamides , Néphrocarcinome , Diarrhée , Fatigue , Tumeurs stromales gastro-intestinales , Syndrome mains-pieds , Hypertension artérielle , Indoles , Nausée , Pipérazines , Leucoencéphalopathie postérieure , Protein-tyrosine kinases , Pyrimidines , Pyrroles , Rifampicine , Stomatite , Mésilate d'imatinibRésumé
Diarrhea-associated hemolytic uremic syndrome(D+ HUS) is induced by enterohemorrhagic Escherichia coli(EHEC) and is characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. The disease is usually transmitted by meat and water contaminated by excreta of domestic animals. We report a son and his mother with diarrhea-associated hemolytic uremic syndrome that spread within the family.
Sujets)
Humains , Atteinte rénale aigüe , Anémie hémolytique , Animaux domestiques , Escherichia coli entérohémorrhagique , Escherichia , Syndrome hémolytique et urémique , Viande , Mères , ThrombopénieRésumé
No abstract available.